For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. This report studies the Pancreatic Cancer Diagnostic market, includes Tumor Biomarker Tests, Imaging, Biopsy and other products.
Scope of the Report:
United States is the largest sales place, with a consumption value market share nearly 32.12% in 2017. Following United States, Europe is the second largest sales place with the consumption market share of 27.65%.
Market competition is intense. Roche, GE Healthcare, Siemens, BD, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Pancreatic Cancer Diagnostic market is valued at 1930 million USD in 2018 and is expected to reach 3050 million USD by the end of 2024, growing at a CAGR of 7.9% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Pancreatic Cancer Diagnostic.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Pancreatic Cancer Diagnostic market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Pancreatic Cancer Diagnostic market by product type and applications/end industries.
Market Segment by Companies, this report covers
- Roche
- GE Healthcare
- Siemens
- BD
- Philips Healthcare
- Hitachi Medical
- Danaher
- Abbott
- Canon Medical Systems
- Myriad Genetics
- Qiagen
- Asuragen
- BioMarker Strategies
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Imaging
- Tumor Biomarker
- Biopsy
- Other
Market Segment by Applications, can be divided into
- Hospitals
- Clinics
- Others